The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Delgado, M.
Right arrow Articles by Ganea, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Delgado, M.
Right arrow Articles by Ganea, D.
The Journal of Immunology, 2001, 166: 2907-2912.
Copyright © 2001 by The American Association of Immunologists

CUTTING EDGE

Cutting Edge: Is Vasoactive Intestinal Peptide a Type 2 Cytokine?

Mario Delgado*,{dagger} and Doina Ganea*

* Department of Biological Sciences, Rutgers University, Newark, NJ 07102; and {dagger} Departamento Biologia Celular, Facultad de Biologia, Universidad Complutense, Madrid, Spain

A component of the chemical language shared by the immune and nervous system is the expression of neuropeptides by immune cells. Vasoactive intestinal peptide (VIP) was shown to be produced by T lymphocytes. Here we investigate whether T cell subsets differentially express VIP. Our studies indicate that, upon specific Ag stimulation, Th2 and T2 cells, but not Th1 and T1 cells derived from TCR transgenic (Tg) mice, express VIP mRNA and protein, and secrete VIP. Following immunization with the specific Ag, significant levels of VIP are present in the serum of syngeneic, non-Tg hosts that receive Th2, but not Th1 Tg cells. Th2 Tg cells recovered from the non-Tg hosts immunized with the specific Ag, but not with an irrelevant Ag, express intracellular VIP. Because VIP is produced by Ag-stimulated type 2 T cells, and differentially affects Th1 and Th2 cells, could VIP be viewed as a type 2 cytokine?




This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
E. Gonzalez-Rey, P. Anderson, and M. Delgado
Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy
Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii70 - iii76.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J.-P. Segain, M. Rolli-Derkinderen, N. Gervois, D. Raingeard de la Bletiere, G. Loirand, and P. Pacaud
Urotensin II is a New Chemotactic Factor for UT Receptor-Expressing Monocytes
J. Immunol., July 15, 2007; 179(2): 901 - 909.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. A. Szliter, S. Lighvani, R. P. Barrett, and L. D. Hazlett
Vasoactive Intestinal Peptide Balances Pro- and Anti-Inflammatory Cytokines in the Pseudomonas aeruginosa-Infected Cornea and Protects against Corneal Perforation
J. Immunol., January 15, 2007; 178(2): 1105 - 1114.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
W. Sun, J. Hong, Y. C. Q. Zang, X. Liu, and J. Z. Zhang
Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis
Int. Immunol., December 1, 2006; 18(12): 1691 - 1700.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M.-C. Huang, A. L. Miller, W. Wang, Y. Kong, S. Paul, and E. J. Goetzl
Differential Signaling of T Cell Generation of IL-4 by Wild-Type and Short-Deletion Variant of Type 2 G Protein-Coupled Receptor for Vasoactive Intestinal Peptide (VPAC2).
J. Immunol., June 1, 2006; 176(11): 6640 - 6646.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
V. Sharma, M. Delgado, and D. Ganea
Granzyme B, a New Player in Activation-Induced Cell Death, Is Down-Regulated by Vasoactive Intestinal Peptide in Th2 but Not Th1 Effectors
J. Immunol., January 1, 2006; 176(1): 97 - 110.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Delgado, E. Gonzalez-Rey, and D. Ganea
The Neuropeptide Vasoactive Intestinal Peptide Generates Tolerogenic Dendritic Cells
J. Immunol., December 1, 2005; 175(11): 7311 - 7324.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
D. POZO and M. DELGADO
The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide?
FASEB J, September 1, 2004; 18(12): 1325 - 1334.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
M. Delgado, D. Pozo, and D. Ganea
The Significance of Vasoactive Intestinal Peptide in Immunomodulation
Pharmacol. Rev., June 1, 2004; 56(2): 249 - 290.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. C. Grimm, R. Newman, Z. Hassim, N. Cuan, S. J. Connor, Y. Le, J. M. Wang, J. J. Oppenheim, and A. R. Lloyd
Cutting Edge: Vasoactive Intestinal Peptide Acts as a Potent Suppressor of Inflammation In Vivo by Trans-Deactivating Chemokine Receptors
J. Immunol., November 15, 2003; 171(10): 4990 - 4994.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Jefford, M. Schnurr, T. Toy, K.-A. Masterman, A. Shin, T. Beecroft, T. Y. Tai, K. Shortman, M. Shackleton, I. D. Davis, et al.
Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli
Blood, September 1, 2003; 102(5): 1753 - 1763.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. K. Voice, C. Grinninger, Y. Kong, Y. Bangale, S. Paul, and E. J. Goetzl
Roles of Vasoactive Intestinal Peptide (VIP) in the Expression of Different Immune Phenotypes by Wild-Type Mice and T Cell-Targeted Type II VIP Receptor Transgenic Mice
J. Immunol., January 1, 2003; 170(1): 308 - 314.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
A. Metwali, A. M. Blum, D. E. Elliott, and J. V. Weinstock
IL-4 inhibits vasoactive intestinal peptide production by macrophages
Am J Physiol Gastrointest Liver Physiol, July 1, 2002; 283(1): G115 - G121.
[Abstract] [Full Text] [PDF]

Home page
 CROBMHome page
D. Ganea and M. Delgado
VASOACTIVE INTESTINAL PEPTIDE (VIP) AND PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AS MODULATORS OF BOTH INNATE AND ADAPTIVE IMMUNITY
Critical Reviews in Oral Biology & Medicine, May 1, 2002; 13(3): 229 - 237.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
E. J. Goetzl, J. K. Voice, S. Shen, G. Dorsam, Y. Kong, K. M. West, C. F. Morrison, and A. J. Harmar
Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC2 receptor for vasoactive intestinal peptide
PNAS, October 31, 2001; (2001) 241503798.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. Martinez, C. Abad, M. Delgado, A. Arranz, M. G. Juarranz, N. Rodriguez-Henche, P. Brabet, J. Leceta, and R. P. Gomariz
Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor
PNAS, January 22, 2002; 99(2): 1053 - 1058.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
E. J. Goetzl, J. K. Voice, S. Shen, G. Dorsam, Y. Kong, K. M. West, C. F. Morrison, and A. J. Harmar
Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC2 receptor for vasoactive intestinal peptide
PNAS, November 20, 2001; 98(24): 13854 - 13859.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.